FindMyKOL

Christopher Dakhil, MD

Basic profile

Cancer Center of Kansas

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionWichita, KS · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Christopher Dakhil is an Oncology physician affiliated with Cancer Center of Kansas. OpenAlex indexes 33 publications with 590 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
33publications

Publications indexed by OpenAlex. Counts exclude supporting files.

590citations

Citations across these publications.

10h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
98companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

98 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Geron Corporation
    Program year20254 payments
    $813
  • Daiichi Sankyo Inc.
    Program year20256 payments
    $561
  • Novartis Pharmaceuticals Corporation
    Program year202518 payments
    $315
All 223 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    46.6%
    PD-1 inhibitor26.9%
    Pembrolizumab53%Nivolumab43%Atezolizumab4%
    Part B, office-administered≥53 patients
    Platinum-based Drug7.6%
    Oxaliplatin96%Carboplatin2%Cisplatin2%
    Part B, office-administered≥31 patients

    + 14 more classes in this area

  • Metabolism & gastrointestinal

    20.8%
    Substance P/Neurokinin-1 Receptor Antagonist11.3%
    Aprepitant100%
    Part B, office-administered≥91 patients
    Serotonin-3 Receptor Antagonist9.2%
    Granisetron81%Ondansetron hydrochloride16%Palonosetron hcl3%Ondansetron Hcl0%Ondansetron Odt0%
    Part D + Part B<11 patients

    + 4 more classes in this area

  • Blood & clotting

    20.6%
    Iron, parenteral preparations15.6%
    Ferric carboxymaltose100%
    Part B, office-administered≥35 patients
    Erythropoiesis-stimulating Agent5%
    Darbepoetin alfa75%Epoetin alfa25%
    Part B, office-administered≥29 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”